title: A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk.
abstract: We describe a value-driven approach to optimizing pharmaceutical portfolios. Our approach incorporates inputs from research and development and commercial functions by simultaneously addressing internal and external factors. This approach differentiates itself from current practices in that it recognizes the impact of study design parameters, sample size in particular, on the portfolio value. We develop an integer programming (IP) model as the basis for Bayesian decision analysis to optimize phase 3 development portfolios using expected net present value as the criterion. We show how this framework can be used to determine optimal sample sizes and trial schedules to maximize the value of a portfolio under budget constraints. We then illustrate the remarkable flexibility of the IP model to answer a variety of 'what-if' questions that reflect situations that arise in practice. We extend the IP model to a stochastic IP model to incorporate uncertainty in the availability of drugs from earlier development phases for phase 3 development in the future. We show how to use stochastic IP to re-optimize the portfolio development strategy over time as new information accumulates and budget changes occur.
authors.affiliation: Cytel Inc., 675 Massachusetts Ave., Cambridge, MA 02139, U.S.A.
authors.forename: Nitin R
authors.initials: NR
authors.lastname: Patel
authors.forename: Suresh
authors.initials: S
authors.lastname: Ankolekar
authors.forename: Zoran
authors.initials: Z
authors.lastname: Antonijevic
authors.forename: Natasa
authors.initials: N
authors.lastname: Rajicic
mesh_terms: D001499:Bayes Theorem; D056808:Biostatistics; D002017:Budgets / Q000706:statistics & numerical data; D017326:Clinical Trials, Phase III as Topic / Q000191:economics* / Q000706:statistics & numerical data*; D003661:Decision Support Techniques; D055808:Drug Discovery / Q000191:economics* / Q000706:statistics & numerical data*; D006801:Humans; D015233:Models, Statistical; D012306:Risk; D013269:Stochastic Processes